ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
Completed
Heidelberg University
2016-06-01
The academic investigator - initiated trial will evaluate in a postapproval setting whether,
and if yes, to what extent and variability, the treatment with lumacaftor in combination with
ivacaftor reverses the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous
subjects with cystic fibrosis under real life conditions.
ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
Completed
University of Giessen
2016-06-01
The academic investigator - initiated trial will evaluate in a postapproval setting whether,
and if yes, to what extent and variability, the treatment with lumacaftor in combination with
ivacaftor reverses the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous
subjects with cystic fibrosis under real life conditions.
ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
Completed
Hannover Medical School
2016-06-01
The academic investigator - initiated trial will evaluate in a postapproval setting whether,
and if yes, to what extent and variability, the treatment with lumacaftor in combination with
ivacaftor reverses the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous
subjects with cystic fibrosis under real life conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
